Investing in 
our future

Investing in our future

Investing in our future

Who are we looking for?

As a fund, we are looking for 100 accredited retail or institutional investors to join us in our long-term mission to create value for our portfolio companies and generate high-alpha returns.

We partner up with conscientious investors who show wonderful empathy for the reality that surrounds them and are sensitive to human suffering. Of course those investors strive for significant profits, but they also want to make a positive impact on society. They actively seek out ways in which they can benefit the world whilst also making shrewd investments.

Infusion 51a welcomes visionary individuals who have an insatiable appetite for innovation and unwavering confidence in tomorrow. If you’re the type of investor that wants to leave the world a better place, we want you on board. We’re looking for those that lead from the front and refuse to standby and do nothing. We want go-getters!

We want partners that are not just looking to make a quick buck. We actively search for those that trust the process and understand making a huge impact in the world won’t happen overnight. In other words, investors who understand the virtues of long-term value creation.

Does it sound like you?

Does it sound like you?

Why getting involved?

$ 0 B
Global Biotechnology market size in 2021 (USD)
$ 0 T
Estimated Global Biotech market size in 2030 (USD)
0 %
Expected Compound Annual Growth Rate (CARG)
$ 0 T
combined value of biotech companies (a 5.4x increase since 2016)
0
healthtech and biotech unicorns were created in 2021 alone

The world we want to create

Better patients outcomes
We dream of solutions that impact the lives of millions of patients worldwide, giving them more chances of successfully overcoming cancer.
Higher survival rate
We want to turn the odds in the favor of underfunded cancer patients and be a source of hope in a picture of despair and difficulties.
More prevention options
The best way to cure a disease is through prevention and early detection. We aim to live in a world of awareness and equal possibilities for all.
Better patients outcomes
We dream of solutions that impact the lives of millions of patients worldwide, giving them more chances of successfully overcoming cancer.
Higher survival rate
We want to turn the odds in the favor of underfunded cancer patients and be a source of hope in a picture of despair and difficulties.
More prevention options
The best way to cure a disease is through prevention and early detection. We aim to live in a world of awareness and equal possibilities for all.

Why we're different

We are determined to bring greater transparency to the fundraising process.
We build relationships founded on high-levels of trust and respect. We set expectations and will always act in the best interest of our clients.
We are determined to bring greater transparency to the fundraising process.
We continually protect our investors by always looking for data-backed opportunities.
The Infusion 51a team provides clients with world-class industry insights and introduces them to assets with real potential. This means making well-educated decisions leveraging data and contrasting information from highly reputable professionals. We are working together across borders and time zones to meet the needs of our customers and help them win.
We continually protect our investors by always looking for data-backed opportunities.
We treat our investors as one of our own
We strive to earn the trust of our clients by being there every step of the way and guiding them on their path to success. We ensure our goals are synonymous with those of our clients.
We treat our investors as one of our own
We thrive under pressure and evolve with the environment
Regardless of the circumstances, our team thrives under pressure, finding efficient, cost-effective and innovative solutions that address any challenge we may encounter.
We thrive under pressure and evolve with the environment
We value loyalty and pride on our spotless reputation
We only believe in reciprocal relationships that benefit both parties. We have developed a well-geared, client-focused process that safeguards all the parties involved. If we win, you win, and vice versa.
We value loyalty and pride on our spotless reputation

Get your Easy Investors Guide

Get your Easy Investors Guide

Companies we've worked with

More about Infusion 51a

We have an in-depth due diligence system that helps us locate and target companies that meet our strict criteria: through data-driven financial analysis, we examine businesses and product viability, leadership quality, work ethic, and past track records.

In parallel, we conduct a deep dive into the companies’ ethos asking ourselves: who stays late? Who leaves early? Who values their employees? And who actually is committed to making long-term changes with their company?

We want to invest in honest, dedicated leaders with the drive and the integrity to reach their goals gallantly.

POTENTIAL HIGHER RETURNS for investors by increasing portfolio companies’ performance through operational acumen and standard process implementation

BETTER ACCESS to negotiated discounts from portfolio acquisitions leading to potentially higher exponential returns

REDUCED COST on operative and administrative tasks by implementing cost-effective solutions

As part of the investing world, it’s a given that large funds and seasoned investors should be great at maximizing your returns on investment. That sounds great, right? But all too often in our industry the mentality seems to be “make profit at whatever cost” often to the detriment of the business involved. 

For example, most Wall Street funds are operating over $5B and are seasoned pros who actively seek out a weak business position and will push to take as much from a company as they can for as little as possible.

Therein lies the problem, these brokers often have little loyalty, and success is measured only by an ability to sell a deal over the likelihood of that investment actually delivering positive returns for investors. 

Why you may ask? Because regardless of how those investments turn out, those on Wall Street will still get a percentage of the money raised and will still get paid. 

Make no mistake: we are fierce negotiators and have a strong sense of accountability. We live for strategy briefs, detailed execution plans, and periodic reports that reveal if we’re on the right track or not.

Infusion 51a operates in a more holistic manner. We provide capital to organizations to enable them to hit milestones, build and implement operations and create value through successful leadership. We then bring in our broker team to capitalize the company at a higher yet fair valuation, which is how our investors make money.

We know actions speak louder than words, this is why we leave our impact-driven mark in every interaction.

From creating a work culture where selflessness, empathy and kindness is rewarded, to attending fundraising events, donating to nonprofit organizations and spreading the word on the importance of funding overlooked diseases, we are fully committed to living by our core values.

Our main impact-focused effort is a Facebook Support Group: “Together Against Glioblastoma”, which we created in partnership with Vivacitas Oncology, one of our Assets Under Management (AUM).

Over the group, we’re determined to share useful resources of the deadliest form of brain cancer, Glioblastoma Multiforme (GBM), for patients and relatives alike, to offer a safe space for venting and asking for support when it’s needed.

With the help of our engaged community, we’ve also developed successful media campaigns, such as #FacesNotNumbers, in which we’re starting to increase visibility on the human stories behind the predominantly devastating statistics of GBM.

Infusion 51a has built such strong, valuable relationships with our investors and the businesses we invest in, that we’re confident any of those would actively agree we’re motivated by a desire to improve our world, create positive change and deliver much-needed care to patients around the globe.

We have an in-depth due diligence system that helps us locate and target companies that meet our strict criteria: through data-driven financial analysis, we examine businesses and product viability, leadership quality, work ethic, and past track records.

In parallel, we conduct a deep dive into the companies’ ethos asking ourselves: who stays late? Who leaves early? Who values their employees? And who actually is committed to making long-term changes with their company?

We want to invest in honest, dedicated leaders with the drive and the integrity to reach their goals gallantly.

POTENTIAL HIGHER RETURNS for investors by increasing portfolio companies’ performance through operational acumen and standard process implementation

BETTER ACCESS to negotiated discounts from portfolio acquisitions leading to potentially higher exponential returns

REDUCED COST on operative and administrative tasks by implementing cost-effective solutions

As part of the investing world, it’s a given that large funds and seasoned investors should be great at maximizing your returns on investment. That sounds great, right? But all too often in our industry the mentality seems to be “make profit at whatever cost” often to the detriment of the business involved. 

For example, most Wall Street funds are operating over $5B and are seasoned pros who actively seek out a weak business position and will push to take as much from a company as they can for as little as possible.

Therein lies the problem, these brokers often have little loyalty, and success is measured only by an ability to sell a deal over the likelihood of that investment actually delivering positive returns for investors. 

Why you may ask? Because regardless of how those investments turn out, those on Wall Street will still get a percentage of the money raised and will still get paid. 

Make no mistake: we are fierce negotiators and have a strong sense of accountability. We live for strategy briefs, detailed execution plans, and periodic reports that reveal if we’re on the right track or not.

Infusion 51a operates in a more holistic manner. We provide capital to organizations to enable them to hit milestones, build and implement operations and create value through successful leadership. We then bring in our broker team to capitalize the company at a higher yet fair valuation, which is how our investors make money.

We know actions speak louder than words, this is why we leave our impact-driven mark in every interaction.

From creating a work culture where selflessness, empathy and kindness is rewarded, to attending fundraising events, donating to nonprofit organizations and spreading the word on the importance of funding overlooked diseases, we are fully committed to living by our core values.

Our main impact-focused effort is a Facebook Support Group: “Together Against Glioblastoma”, which we created in partnership with Vivacitas Oncology, one of our Assets Under Management (AUM).

Over the group, we’re determined to share useful resources of the deadliest form of brain cancer, Glioblastoma Multiforme (GBM), for patients and relatives alike, to offer a safe space for venting and asking for support when it’s needed.

With the help of our engaged community, we’ve also developed successful media campaigns, such as #FacesNotNumbers, in which we’re starting to increase visibility on the human stories behind the predominantly devastating statistics of GBM.

Infusion 51a has built such strong, valuable relationships with our investors and the businesses we invest in, that we’re confident any of those would actively agree we’re motivated by a desire to improve our world, create positive change and deliver much-needed care to patients around the globe.

Technical investment questions

A fund is a collective investment institution constituted by fund managers (General Partners) and investors (limited partners). Fund operators wisely manage the capital of their partners and present them with broader investment opportunities, greater management expertise, and investment fees discounts than individual investors would hardly be able to obtain on their own. 

Limited Partners have no operational responsibilities and are solely responsible for putting their money in and expecting the returns.

In essence, people investing in a fund like ours become part owners of the fund and, therefore, own equity in the business.

If an investor puts $1M into a $20M fund, the fund will now have $21M and the investor would have their proportionate equity. If the fund’s value grows to $42M then that investor’s equity would go to $2M. If the fund were to go down to $10.5M,  that investor’s equity would be worth $500K.

The role of General Partners in a fund is to ensure their investors’ money is put to good use, locating it smartly according to their previous experiences and their market knowledge, in order to maximize the possibilities of increasing profits for investors.

Fund operations are paid for by taking a yearly 2% management fee of the overall value of the fund. This is broken down quarterly, resulting in 0.5% per quarter.

At Infusion 51a, we are taking 2% on approximately $10M, which is roughly $200,000 a year to operate the entire fund.

GPs also receive 20% of the growth of the fund’s value. For example: let’s say a fund grows from $20M to $100M, which equals $80M in profit. The investors would receive 80% of the profit ($64M) and the GPs would receive 20% ($16M).

By law, we are only allowed 100 accredited investors

An accredited investor is an individual or a business entity that is allowed to trade securities that may not be registered with financial authorities.

To qualify as an accredited investor, you must:

  • Have $1M net worth outside of your home, or
  • Have made $200K (if single) a year for the past 2 consecutive years, or $300K (if married) combined with your spouse’s income —besides reasonably expecting the same income level in the current year.

An institution is an organization that is in the business of investing or has dedicated divisions to invest. An example would be the Navy’s Endowment Department, a financial institution, other funds, banks, Registered Advisors, Financial Advisors, etc.

On the other hand, a retail investor is a regular citizen who, regardless of their source of income, decides to grow their money by investing in stocks, real estate, or bonds. The higher retail investors’ net worth, the more sophisticated they are and the more likely it is that they have advisors that help them make decisions. There are also Ultra High Net Worth Individuals (UHNWIs) who have built massive amounts of wealth, although they are still “just” retail investors.

As a recent investment fund, it’s normal for investors to look for our background in the industry and for any hard proof that their money won’t go to waste.

However, the unpredictability of the market and the fast-shifting biotech industry is something not even big firms can escape from.

Just like with any other fund, there are higher risks in opportunities with higher potential for better returns.

We cannot foresee the results any of our operations will get, but we can promise we’ll look out for our investors’ best interests every damn chance we have.

A fund is a collective investment institution constituted by fund managers (General Partners) and investors (limited partners). Fund operators wisely manage the capital of their partners and present them with broader investment opportunities, greater management expertise, and investment fees discounts than individual investors would hardly be able to obtain on their own. 

Limited Partners have no operational responsibilities and are solely responsible for putting their money in and expecting the returns.

In essence, people investing in a fund like ours become part owners of the fund and, therefore, own equity in the business.

If an investor puts $1M into a $20M fund, the fund will now have $21M and the investor would have their proportionate equity. If the fund’s value grows to $42M then that investor’s equity would go to $2M. If the fund were to go down to $10.5M,  that investor’s equity would be worth $500K.

The role of General Partners in a fund is to ensure their investors’ money is put to good use, locating it smartly according to their previous experiences and their market knowledge, in order to maximize the possibilities of increasing profits for investors.

Fund operations are paid for by taking a yearly 2% management fee of the overall value of the fund. This is broken down quarterly, resulting in 0.5% per quarter.

At Infusion 51a, we are taking 2% on approximately $10M, which is roughly $200,000 a year to operate the entire fund.

GPs also receive 20% of the growth of the fund’s value. For example: let’s say a fund grows from $20M to $100M, which equals $80M in profit. The investors would receive 80% of the profit ($64M) and the GPs would receive 20% ($16M).

By law, we are only allowed 100 accredited investors

An accredited investor is an individual or a business entity that is allowed to trade securities that may not be registered with financial authorities.

To qualify as an accredited investor, you must:

  • Have $1M net worth outside of your home, or
  • Have made $200K (if single) a year for the past 2 consecutive years, or $300K (if married) combined with your spouse’s income —besides reasonably expecting the same income level in the current year.

An institution is an organization that is in the business of investing or has dedicated divisions to invest. An example would be the Navy’s Endowment Department, a financial institution, other funds, banks, Registered Advisors, Financial Advisors, etc.

On the other hand, a retail investor is a regular citizen who, regardless of their source of income, decides to grow their money by investing in stocks, real estate, or bonds. The higher retail investors’ net worth, the more sophisticated they are and the more likely it is that they have advisors that help them make decisions. There are also Ultra High Net Worth Individuals (UHNWIs) who have built massive amounts of wealth, although they are still “just” retail investors.

As a recent investment fund, it’s normal for investors to look for our background in the industry and for any hard proof that their money won’t go to waste.

However, the unpredictability of the market and the fast-shifting biotech industry is something not even big firms can escape from.

Just like with any other fund, there are higher risks in opportunities with higher potential for better returns.

We cannot foresee the results any of our operations will get, but we can promise we’ll look out for our investors’ best interests every damn chance we have.

Still have questions? Let's book a call!

Still have questions? Let's book a call!